M5717首次人体研究:安全性、药代动力学及抗疟活性
该研究在健康志愿者中评估了新型疟原虫翻译延伸因子2抑制剂M5717的安全性、药代动力学和抗疟活性。单次递增剂量研究(50-2100 mg)显示不良事件多为轻中度,≥1800 mg组出现短暂口腔感觉减退和视力模糊;志愿者感染研究显示所有受试者寄生虫均清除,但150 mg和400 mg组分别有50%和25%复发,部分复发株检出耐药相关突变。
要点
- M5717总体安全,不良事件轻中度且短暂,但≥1250 mg剂量不良事件频率增加。
- ≥200 mg剂量下半衰期长达146-193小时,支持单剂量给药开发。
- 所有受试者寄生虫均清除,但150 mg和400 mg组复发率分别为50%和25%。
核心结论
- M5717的安全性、药代动力学和抗疟活性支持其作为单剂量抗疟联合疗法组分或疟疾预防药物进行开发。
研究设计与样本
- 两部分、单中心首次人体试验,在澳大利亚布里斯班进行。
- 第一部分为双盲、随机、安慰剂对照、单次递增剂量研究,纳入66名男性,随机分配至9个剂量队列(50、100、200、400、600、1000、1250、1800或2100 mg),按3:1随机接受M5717或安慰剂。
- 第二部分为开放标签、非随机志愿者感染研究,使用恶性疟原虫诱导血阶段疟疾模型,纳入22名疟疾初治男性,分配至150 mg(6人)、400 mg(8人)和800 mg(8人)队列。
主要发现
- 单次递增剂量研究中,无严重不良事件;所有M5717相关不良事件均为轻或中度且短暂,剂量高于1250 mg时频率增加。
- 1800 mg或2100 mg组观察到短暂口腔感觉减退(3人)和视力模糊(4人),构成未知风险,2100 mg队列两名哨兵给药后暂停进一步给药。
- 给药后1-7小时达最大血药浓度,≥200 mg剂量下半衰期为146-193小时。
- 所有志愿者感染研究受试者均出现寄生虫清除,呈双相:初始缓慢清除持续35-55小时,随后快速清除。
- 150 mg组6人中3人(50%)复发,400 mg组8人中2人(25%)复发;4例复发中检出耐药相关基因突变(150 mg组2例,400 mg组2例)。
关键数值与推荐
- 单次递增剂量研究主要结局为安全性和耐受性,通过不良事件频率和严重程度评估。
- 志愿者感染研究主要结局为药代动力学特征和寄生虫清除动力学(寄生虫减少比率及清除半衰期)。
临床怎么用
- M5717支持开发为单剂量抗疟联合疗法组分或用于疟疾预防。
- 临床试验中需监测剂量相关不良事件,尤其是高剂量下的口腔感觉减退和视力模糊。
- 需关注复发及耐药相关突变,后续开发应评估联合用药以抑制耐药。
局限性
- 研究纳入健康志愿者(感染研究为疟疾初治男性),结果外推至患者人群需谨慎。
- 样本量小,各剂量队列仅6-8人,安全性及复发率估计精度有限。
- 2100 mg队列因未知风险暂停,高剂量安全性数据不完整。
- 复发株耐药相关突变仅为探索性结果,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: M5717 is the first plasmodium translation elongation factor 2 inhibitor to reach clinical development as an antimalarial. We aimed to characterise the safety, pharmacokinetics, and antimalarial activity of M5717 in healthy volunteers. METHODS: This first-in-human study was a two-part, single-centre clinical trial done in Brisbane, QLD, Australia. Part one was a double-blind, randomised, placebo-controlled, single ascending dose study in which participants were enrolled into one of nine dose cohorts (50, 100, 200, 400, 600, 1000, 1250, 1800, or 2100 mg) and randomly assigned (3:1) to M5717 or placebo. A sentinel dosing strategy was used for each dose cohort whereby two participants (one assigned to M5717 and one assigned to placebo) were initially randomised and dosed. Randomisation schedules were generated electronically by independent, unblinded statisticians. Part two was an open-label, non-randomised volunteer infection study using the Plasmodium falciparum induced blood-stage malaria model in which participants were enrolled into three dose cohorts. Healthy men and women of non-childbearing potential aged 18-55 years were eligible for inclusion; individuals in the volunteer infection study were required to be malaria naive. Safety and tolerability (primary outcome of the single ascending dose study and secondary outcome of the volunteer infection study) were assessed by frequency and severity of adverse events. The pharmacokinetic profile of M5717 was also characterised (primary outcome of the volunteer infection study and secondary outcome of the single ascending dose study). Parasite clearance kinetics (primary outcome of the volunteer infection study) were assessed by the parasite reduction ratio and the corresponding parasite clearance half-life; the incidence of recrudescence up to day 28 was determined (secondary outcome of the volunteer infection study). Recrudescent parasites were tested for genetic mutations (exploratory outcome). The trial is registered with ClinicalTrials.gov (NCT03261401). FINDINGS: Between Aug 28, 2017, and June 14, 2019, 221 individuals were assessed for eligibility, of whom 66 men were enrolled in the single ascending dose study (eight per cohort for 50-1800 mg cohorts, randomised three M5717 to one placebo, and two in the 2100 mg cohort, randomised one M5717 to one placebo) and 22 men were enrolled in the volunteer infection study (six in the 150 mg cohort and eight each in the 400 mg and 800 mg cohorts). No adverse event was serious; all M5717-related adverse events were mild or moderate in severity and transient, with increased frequency observed at doses above 1250 mg. In the single ascending dose study, treatment-related adverse events occurred in three of 17 individuals in the placebo group; no individual in the 50 mg, 100 mg, or 200 mg groups; one of six individuals in each of the 400 mg, 1000 mg, and 1250 mg groups; two of six individuals in the 600 mg group; and in all individuals in the 1800 mg and 2100 mg groups. In the volunteer infection study, M5717-related adverse events occurred in no participants in the 150 mg or 800 mg groups and in one of eight participants in the 400 mg group. Transient oral hypoesthesia (in three participants) and blurred vision (in four participants) were observed in the 1800 mg or 2100 mg groups and constituted an unknown risk; thus, further dosing was suspended after dosing of the two sentinel individuals in the 2100 mg cohort. Maximum blood concentrations occurred 1-7 h after dosing, and a long half-life was observed (146-193 h at doses ≥200 mg). Parasite clearance occurred in all participants and was biphasic, characterised by initial slow clearance lasting 35-55 h (half-life 231·1 h [95% CI 40·9 to not reached] for 150 mg, 60·4 h [38·6 to 138·6] for 400 mg, and 24·7 h [20·4 to 31·3] for 800 mg), followed by rapid clearance (half-life 3·5 h [3·1 to 4·0] for 150 mg, 3·9 h [3·3 to 4·8] for 400 mg, and 5·5 h [4·8 to 6·4] for 800 mg). Recrudescence occurred in three (50%) of six individuals dosed with 150 mg and two (25%) of eight individuals dosed with 400 mg. Genetic mutations associated with resistance were detected in four cases of parasite recrudescence (two individuals dosed with 150 mg and two dosed with 400 mg). INTERPRETATION: The safety, pharmacokinetics, and antimalarial activity of M5717 support its development as a component of a single-dose antimalarial combination therapy or for malaria prophylaxis. FUNDING: Wellcome Trust and the healthcare business of Merck KGaA, Darmstadt, Germany.
引用
- McCarthy JS, Yalkinoglu Ö, Odedra A, et al. Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study. Lancet Infect Dis. 2021. PMID: 34715032. doi:10.1016/S1473-3099(21)00252-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。